Back to Cell Types

BFTC-905Homo sapiens (Human)Cancer cell line

Also known as: Black Foot disease Transitional Carcinoma 905, BFTC905, BFTC 905

🤖 AI SummaryBased on 10 publications

Quick Overview

Human bladder cancer cell line with known mutations and genetic diversity.

Detailed Summary

BFTC-905 is a human bladder cancer cell line derived from transitional cell carcinoma. It is characterized by specific genetic mutations, including those in the TERT promoter and other key oncogenes. This cell line is used in research to study the molecular mechanisms of bladder cancer, including the role of telomerase activation and genetic instability. The cell line has been utilized in studies examining the impact of mutations on tumor progression and therapeutic responses. Its genetic profile provides insights into the heterogeneity of bladder cancer and aids in the development of targeted therapies.

Research Applications

Molecular mechanisms of bladder cancerTelomerase activation studiesGenetic instability and mutation analysisTherapeutic response evaluation

Key Characteristics

TERT promoter mutationsGenetic diversityTransitional cell carcinoma origin

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1083
Species	Homo sapiens (Human)
Tissue Source	Urinary bladder[UBERON:UBERON_0001255]

Donor Information

Age	51
Age Category	Adult
Sex	Female
Race	asian

Disease Information

Disease	Bladder carcinoma
Lineage	Bladder/Urinary Tract
Subtype	Bladder Urothelial Carcinoma
OncoTree Code	BLCA

DepMap Information

Source Type	DSMZ
Source ID	ACH-000802_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	c.673-2A>T (IVS6-2A>T)	Unspecified	Splice acceptor mutation	PubMed=11799138
MutationSimple	NRAS	p.Gln61Leu (c.182A>T)	Unspecified	-	PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12

D13S317

11

D16S539

12

D18S51

16

D19S433

14

D21S11

30

D2S1338

18,23

D3S1358

16

D5S818

13

D7S820

9,12

D8S1179

13,15

FGA

22

Penta D

9

Penta E

11

TH01

7,8

TPOX

8,9

vWA

14,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.

Knowles M.A.

Genes Chromosomes Cancer 43:315-328(2005).

Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan.

Lin J.S.

Anticancer Res. 16:1797-1804(1996).